Appendix 4E Preliminary Final Report
Released
Released
Announcement PDF
Immuron Limited
Appendix 4E
Preliminary final report
1. Company details
Name of entity:
ABN:
Reporting period:
Previous period:
Immuron Limited
80 063 114 045
For the year ended 30 June 2025
For the year ended 30 June 2024
2. Results for announcement to the market
$
Revenue from ordinary activities
up
48.6% to
7,287,002
Loss from ordinary activities after tax attributable to the members of
Immuron Limited
down
24.3% to
(5,253,209)
Loss for the year attributable to the members of Immuron Limited
down
24.3% to
(5,253,209)
3. Net tangible assets
Consolidated
2025
2024
Cents
Cents
Net tangible asset backing (per security)
3.39
5.51
The calculation of net tangible assets excludes right-of-use assets arising from AASB 16 Leases.
4. Explanation of results
The reported loss after tax of the current financial year of $5,253,209 (2024: $6,936,957) is after fully expensing the
company’s research and development expenditure of $3,597,296 incurred during the year (2024: $5,375,461). Of which,
$146,252 (2024: $2,599,458) was funded by the R&D grant from Medical Technology Enterprise Consortium (MTEC).
The revenue from contracts with customers for the year was $7,287,002, which is an increase of 48.6% from the prior
financial year (2024: $4,902,865), primarily due to the sales increase in the Australian and North American markets for
Travelan®. We anticipate that revenues from sales of our Travelan® product will continue to increase in the future.
As at 30 June 2025, the company’s cash position was $2,830,526 (30 June 2024: $11,657,315). The company had trade
and other receivables of $1,888,370 (30 June 2024: $1,387,573). This receivables amount includes future receivables from
the Australian Government under the R&D Tax Incentive program. The company had other current assets of $3,486,744
(30 June 2024: $96,841). This other current assets amount includes a 90-day fixed term deposit of $3,036,278 (30 June
2024: Nil), which matured on 27 July 2025.
The preliminary final report follows, with the further details to be included in the audited financial statements to be released
by 30 September 2025.
5. Distributions
No dividends have been paid or declared by the company for the current financial year. No dividends were paid for the
previous financial year.
6. Changes in controlled entities
There have been no changes in controlled entities during the year ended 30 June 2025.
Immuron Limited
Appendix 4E
Preliminary final report
7. Details of associates and joint venture entities
Name of entity
Ateria Health Limited
Ownership interest held by
the Group
2025
2024
Place of business/country of incorporation
%
%
United Kingdom
23.6%
23.6%
As at 30 June 2025, Immuron has a 23.61% interest in Ateria. Immuron is deemed to have significant influence over Ateria.
8. Audit
The financial statements of Immuron Limited (the 'Group') are currently in the process of being audited. The audited
financial statements along with the independent auditor report for the year end 30 June 2025 will be provided in the due
course.
Immuron Limited
Consolidated statement of profit or loss and other comprehensive income
For the year ended 30 June 2025
Note
Revenue from contracts with customers
Cost of goods sold
1
Consolidated
2025
2024
$
$
7,287,002
(2,521,903)
4,902,865
(1,566,068)
4,765,099
3,336,797
1,374,283
12,183
1,386,466
3,408,199
(27,603)
(557,676)
2,822,920
Expenses
General and administrative expenses
Research and development expenses
Selling and marketing expenses
(4,483,623)
(3,597,296)
(3,452,416)
(4,555,726)
(5,375,461)
(2,029,648)
Operating loss
(5,381,770)
(5,801,118)
135,866
(7,305)
-
327,756
(7,576)
(1,456,019)
(5,253,209)
(6,936,957)
-
-
(5,253,209)
(6,936,957)
Items that may be reclassified subsequently to profit or loss
Exchange differences on translation of foreign operations (expense)/income
(1,358)
2,266
Other comprehensive (loss)/income for the year
(1,358)
2,266
Total comprehensive loss for the year
(5,254,567)
(6,934,691)
Loss per share for profit attributable to the ordinary equity holders of the
company:
Cents
Cents
Gross profit
Other income
Net foreign exchange gains/(losses)
Fair value losses to financial assets
Total other income including gains/(losses)
2
Finance income
Finance expenses
Share of loss from equity accounted associate
10
Loss before income tax expense
Income tax expense
Loss after income tax expense for the year attributable to the members of
Immuron Limited
Other comprehensive (loss)/income
Basic and diluted loss per share
(2.27)
(3.04)
The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with
the accompanying notes
1
Immuron Limited
Consolidated statement of financial position
As at 30 June 2025
Note
Consolidated
2025
2024
$
$
Assets
Current assets
Cash and cash equivalents
Trade and other receivables
Inventories
Other current assets
Total current assets
2,830,526
1,888,370
1,772,363
3,486,744
9,978,003
11,657,315
1,387,573
1,584,608
96,841
14,726,337
113,950
666
114,616
154,347
669,285
823,632
10,092,619
15,549,969
1,529,434
391,503
45,272
1,966,209
2,135,852
522,571
40,556
2,698,979
22,722
71,855
94,577
8,605
132,941
141,546
Total liabilities
2,060,786
2,840,525
Net assets
8,031,833
12,709,444
3
4
Non-current assets
Property, plant and equipment
Inventories
Total non-current assets
Total assets
Liabilities
Current liabilities
Trade and other payables
Employee benefits
Other current liabilities
Total current liabilities
Non-current liabilities
Employee benefits
Other non-current liabilities
Total non-current liabilities
Equity
Share capital
Other reserves
Accumulated losses
5
6
Total equity
88,872,756
88,504,043
1,639,504
3,173,797
(82,480,427) (78,968,396)
8,031,833
12,709,444
The above consolidated statement of financial position should be read in conjunction with the accompanying notes
2
Immuron Limited
Consolidated statement of changes in equity
For the year ended 30 June 2025
Consolidated
Issued
capital
$
Balance at 1 July 2023
88,436,263
3,235,969
(72,055,396)
19,616,836
Loss after income tax expense for the year
Other comprehensive income for the year
-
2,266
(6,936,957)
-
(6,936,957)
2,266
Total comprehensive income/(loss) for the year
-
2,266
(6,936,957)
(6,934,691)
67,780
-
15,231
(11,932)
(43,780)
(23,957)
23,957
15,231
(11,932)
24,000
-
Balance at 30 June 2024
88,504,043
3,173,797
(78,968,396)
12,709,444
Consolidated
Issued
capital
$
Balance at 1 July 2024
88,504,043
3,173,797
(78,968,396)
12,709,444
Loss after income tax expense for the year
Other comprehensive loss for the year
-
(1,358)
(5,253,209)
-
(5,253,209)
(1,358)
Total comprehensive loss for the year
-
(1,358)
(5,253,209)
(5,254,567)
272,713
-
-
272,713
96,000
64,755
(1,741,178)
239,488
(96,000)
1,741,178
-
64,755
239,488
-
88,872,756
1,639,504
(82,480,427)
8,031,833
Transactions with members in their capacity as members:
Options and warrants vested in the year
Options and warrants issued/expensed (net of adjustments)
Options and warrants exercised
Options and warrants forfeited
Transactions with members in their capacity as members:
Shares issued, net of transaction costs (note 5)
Options and warrants issued/expensed (net of adjustments)
(note 6)
Options and warrants lapsed/expired (note 6)
Performance rights issued/expensed (note 6)
Performance rights exercised (note 6)
Balance at 30 June 2025
Accumulated
losses
Total equity
$
$
Reserves
$
Accumulated
losses
Total equity
$
$
Reserves
$
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes
3
Immuron Limited
Consolidated statement of cash flows
For the year ended 30 June 2025
Consolidated
2025
2024
$
$
Cash flows from operating activities
Receipts from customers (inclusive of GST)
Payments to suppliers (inclusive of GST)
Australian R&D tax incentive refund
Grants received from government and non-government sources
7,592,577
4,734,350
(14,772,687) (12,910,753)
768,433
395,001
274,728
1,901,263
Net cash used in operating activities
(6,136,949)
(5,880,139)
Cash flows from investing activities
Payment for property, plant and equipment
Payments for term deposit
Interest received
(3,036,278)
135,866
(195)
327,756
Net cash (used in)/from investing activities
(2,900,412)
327,561
Cash flows from financing activities
Proceeds from issues of shares
Share issue transaction costs
Principal elements of lease payments
Interest and other costs of finance paid
396,827
(124,114)
(65,661)
(7,305)
24,000
(15,595)
(7,576)
Net cash from financing activities
199,747
829
Net decrease in cash and cash equivalents
Cash and cash equivalents at the beginning of the financial year
Effects of exchange rate changes on cash and cash equivalents
(8,837,614)
11,657,315
10,825
(5,551,749)
17,159,764
49,300
Cash and cash equivalents at the end of the financial year
2,830,526
11,657,315
The above consolidated statement of cash flows should be read in conjunction with the accompanying notes
4
Immuron Limited
Notes to the consolidated financial statements
30 June 2025
1. Revenue from contract with customers
The Group derives revenue from the transfer of hyperimmune products at a point in time in the following major product
lines and geographical regions:
Consolidated
2025
2024
$
$
Hyperimmune products revenue
Travelan - Australia
Travelan - United States
Travelan - Canada
Protectyn - Australia
5,201,385
1,658,336
378,706
48,575
3,702,876
1,075,614
80,888
43,487
Revenue from external customers
7,287,002
4,902,865
2. Other income
Consolidated
2025
2024
$
$
Australian R&D tax incentive refund
MTEC R&D grant
HJF R&D grant
EMDG grant
Other income
1,073,355
146,252
124,164
30,512
764,981
2,599,458
28,000
15,760
1,374,283
3,408,199
(i) Fair value of R&D tax incentive
The Group's research and development (R&D) activities are eligible under an Australian government tax incentive for
eligible expenditure. Management has assessed these activities and expenditure to determine which are likely to be eligible
under the incentive scheme. Amounts are recognised when it has been established that the conditions of the tax incentive
have been met and that the expected amount can be reliably measured. For the year ended 30 June 2025, the Group has
included an item in other income of $1,073,355 (2024: $764,981).
3. Trade and other receivables
Consolidated
2025
2024
$
$
Current assets
Trade receivables
Less: Allowance for expected credit losses
826,857
(35,466)
791,391
607,436
(16,233)
591,203
Accrued income - Australian R&D tax incentive refund
Other income receivables - other grants
Other receivables
1,073,291
23,688
768,370
28,000
-
Total trade and other receivables
1,888,370
1,387,573
Classification as trade receivables
Trade receivables are amounts due from customers for goods sold or services performed in the ordinary course of
business. They are generally due for settlement within 30 days and therefore are all classified as current. Trade receivables
are recognised initially at the amount of consideration that is unconditional unless they contain significant financing
components, when they are recognised at fair value. The Group holds the trade receivables with the objective to collect
the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest
method.
Accrued receivables
These amounts primarily comprise receivables from the Australian Taxation Office in relation to the R&D tax incentive.
5
Immuron Limited
Notes to the consolidated financial statements
30 June 2025
3. Trade and other receivables (continued)
Fair value of trade and other receivables
Due to the short-term nature of the current receivables, their carrying amount is considered to be the same as their fair
value.
4. Other current assets
Consolidated
2025
2024
$
$
Prepayments
Term deposits
Other current assets
442,800
3,036,278
7,666
86,798
10,043
3,486,744
96,841
The Group entered into a 90-day fixed term deposit, which matured on 27 July 2025. Term deposits are presented as
Other Current Assets as they are not considered highly liquid instruments readily convertible to cash and cash equivalents.
The deposit was held to maturity in accordance with the Group's investment policy.
5. Share capital
Consolidated
2024
2025
Shares
$
2025
Shares
Ordinary shares - fully paid
Transaction costs arising on ordinary share issues
2024
$
233,959,013
-
227,998,346
-
98,581,947
(9,709,191)
98,089,120
(9,585,077)
233,959,013
227,998,346
88,872,756
88,504,043
Shares
$
227,798,346
200,000
-
88,436,263
67,780
-
227,998,346
88,504,043
1,147,083
2,579,760
1,801,680
83,000
226,567
152,300
179,664
135,800
116,680
233,959,013
13,000
9,744
8,216
(124,114)
88,872,756
Movements in ordinary shares:
Details
Date
Balance
Issue at $0.12 on exercise of unlisted options (2024-03-12)
Less: Transaction costs arising on share issues
1 July 2023
Balance
30 June 2024
Issue of shares on the exercise of performance rights at $0.0 per
share (2024-10-07)
Issue at US$2.1784 pursuant to At The Market facility (2025-01-08)
Issue at US$2.0971 pursuant to At The Market facility (2025-01-15)
Issue of shares on the exercise of performance rights at $0.0 per
share (2025-04-10)
Issue at US$1.8435 pursuant to At The Market facility (2025-05-29)
Issue at US$1.8286 pursuant to At The Market facility (2025-06-03)
Less: Transaction costs arising on share issues
Balance
30 June 2025
Rights of each type of share
Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the company in proportion
to the number of shares held. On a show of hands every holder of ordinary shares present at a meeting or by proxy, is
entitled to one vote upon a poll every holder is entitled to one vote per share held. The ordinary shares have no par value.
6
Immuron Limited
Notes to the consolidated financial statements
30 June 2025
6. Other reserves
Share-based
payments
$
Foreign
currency
translation
$
3,123,759
-
112,210
2,266
3,235,969
2,266
15,231
(11,932)
(43,780)
(23,957)
-
15,231
(11,932)
(43,780)
(23,957)
Balance at 30 June 2024
Currency translation differences
3,059,321
-
114,476
(1,358)
3,173,797
(1,358)
Transactions with owners in their capacity as owners:
Options and warrants issued/expensed (net of adjustments) (note 6(ii))
Options and warrants lapsed/expired (note 6(ii))
Performance rights issued/expensed (note 6(ii))
Performance rights exercised (note 6(ii))
64,755
(1,741,178)
239,488
(96,000)
-
64,755
(1,741,178)
239,488
(96,000)
Balance at 30 June 2025
1,526,386
113,118
1,639,504
Consolidated
Balance at 1 July 2023
Currency translation differences
Transactions with owners in their capacity as owners:
Options and warrants vested in the year
Options and warrants issued/expensed (net of adjustments)
Options and warrants exercised
Options and warrants lapsed/expired
Total
$
(i) Nature and purpose of other reserves:
Share-based payments
The share-based payment reserve records items recognised as expenses on valuation of share options and warrants
issued to key management personnel, other employees and eligible contractors.
Foreign currency translation
Exchange differences arising on translation of foreign controlled entities are recognised in other comprehensive income
as described in note and accumulated in a separate reserve within equity.
(ii) Movements in options, warrants and performance rights:
Number of
options or
performance
rights
Details
$
Balance as at 1 July 2023
Options issued in the year (net of adjustments)
Exercise of unlisted options at $0.12 (2024-03-12)
Lapse of unexercised options
Share-based payments expense for options previously issued
Performance rights issued in the year
Balance as at 30 June 2024
12,879,720
1,000,000
(200,000)
(173,600)
1,688,839
15,194,959
3,123,759
(11,932)
(43,780)
(23,957)
15,231
3,059,321
Options issued in the year (net of adjustments)
Lapse of unexercised options
Share-based payments expense for options previously issued
Exercise of performance rights
Performance rights issued in the year
Lapse of performance rights issued in the year
3,000,000
(8,016,120)
(1,326,747)
5,386,810
(285,741)
55,584
(1,741,178)
9,171
(96,000)
239,488
-
Balance as at 30 June 2025
13,953,161
1,526,386
7
Immuron Limited
Notes to the consolidated financial statements
30 June 2025
7. Share-based payments
Performance rights
Performance rights which can be settled in shares, were granted to key management personnel and employees during the
year. The expense for the year ended 30 June 2025 was $239,488. The performance rights are based on non-market
weighted key performance indicators (KPIs) and have been expensed over the service period, based on the probability
the KPIs being achieved. The performance rights are expected to vest between one and five years.
Options
Options were approved at the Annual General Meeting, held on 18 November 2024 for Prof. Ravi Savarirayan and Mr.
Daniel Pollock of 1,000,000 each. The option exercise price is $0.145 and they have an expiry date of 20 August 2028.
The expense for the year was $34,952.
Options were granted to Dr. Jeanette Joughin on 19 June 2024 but were subject to shareholder approval obtained on 18
November 2024. The expense of $20,632 recorded in the year includes an adjustment for the revised estimate of fair value
on the grant date of 18 November 2024.
Fair value is determined using the Black-Scholes option pricing model that takes into account the exercise price, term of
the award, security price at grant date, expected volatility, expected dividend yield and the risk-free interest rate.
The model inputs for the options granted during the year:
Grant date
Expiry
date
Exercise
price ($A)
No. of
options
18-NOV-24
18-NOV-24
20-AUG-28
19-JUN-28
$0.145
$0.130
2,000,000
1,000,000
Share
Expected
price at
volatility
grant date
$0.079
$0.079
74.51%
75.72%
Dividend
yield
0.00%
0.00%
Risk-free Fair value
interest
at grant
rate
date per
option
4.15%
$0.033
4.15%
$0.035
8. Events after the reporting period
At The Market Capital Raising
In July 2025, Immuron Limited (ASX: IMC), raised gross proceeds of USD$1,822,322 (AUD$2,809,177) through an At The
Market Facility comprising 34,260,960 shares at an average issue price of of USD$0.053 (AUD$0.082) per share.
This capital raising initiative does not provide evidence of conditions that existed at 30 June 2025 and is therefore classified
as a non-adjusting event in accordance with AASB 110 Events after the Reporting Period. No adjustments have been
made to the financial statements as a result of this transaction.
No other matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect
the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.
9. Principal subsidiaries
The Group’s principal subsidiaries at 30 June 2025 are set out below. Unless otherwise stated, they have share capital
consisting solely of ordinary shares that are held directly by the Group, and the proportion of ownership interests held
equals the voting rights held by the Group. The country of incorporation or registration is also their principal place of
business.
Name of entity
Principal place of business /
Country of incorporation
Immuron Inc.
Immuron Canada Limited
Anadis ESP Pty Ltd
United States
Canada
Australia
8
Ownership interest by the
Group
2025
2024
%
%
100%
100%
100%
100%
100%
100%
Immuron Limited
Notes to the consolidated financial statements
30 June 2025
10. Interests in associates
Immuron Limited has a 23.6% interest in Ateria Health Limited (Ateria). The investment was impaired to NIL during the
2024 financial year and there has been no changes to this in the year ended 30 June 2025.
Name of entity
Principal place of business /
Country of incorporation
Ateria Health Limited
United Kingdom
Ownership interest held by
the Group
2025
2024
%
%
23.6%
23.6%
Summarised financial information for associates
Consolidated
2025
2024
$
$
Share of loss for the year
-
(1,456,019)
Consolidated
2025
2024
$
$
Recognised in:
Share of loss for the year - 23.6% (2024: 23.6%)
Impairment of investment in associate
-
(291,711)
(1,164,308)
-
(1,456,019)
The carrying amount of investment in associate is NIL, therefore no share of the loss has been recognised for the year
ended 30 June 2025.
9
Share your feedback
Discover